> Detailanzeige

Wilhelmy, Florian [Verfasser:in]; Hantsche, Annika [Verfasser:in]; Gaier, Michael [Verfasser:in]; Kasper, Johannes [Verfasser:in]; Fehrenbach, Michael Karl [Verfasser:in]; Oesemann, Rene [Verfasser:in]; Meixensberger, Jürgen [Verfasser:in]; Lindner, Dirk [Verfasser:in]

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
  • Beteiligte: Wilhelmy, Florian [Verfasser:in]; Hantsche, Annika [Verfasser:in]; Gaier, Michael [Verfasser:in]; Kasper, Johannes [Verfasser:in]; Fehrenbach, Michael Karl [Verfasser:in]; Oesemann, Rene [Verfasser:in]; Meixensberger, Jürgen [Verfasser:in]; Lindner, Dirk [Verfasser:in]
  • Erschienen: Basel: MDPI, [2024]
  • Erschienen in: Neurology International ; 13,2 (2021), Seite 202-206
  • Sprache: Englisch
  • DOI: 10.3390/neurolint13020021
  • Schlagwörter: African swine fever ; tinzaparin ; perioperative anticoagulation ; neurosurgery ; heparin shortage ; nadroparin
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Background: An outbreak of African swine fever (ASF) in China in 2020 has led to anunprecedented shortage of nadroparin. Most patients, especially those kept in hospital for surgery,are currently treated with prophylactic anticoagulation (AC). In search of alternatives for nadroparin(fraxiparine), we found no sufficient data on alternatives for neurosurgical patients, such as tinzaparinof European origin. We compared nadroparin and tinzaparin concerning adverse events(bleeding versus thromboembolic events) in neurosurgical patients. Methods: Between 2012 and2018, 517 neurosurgical patients with benign and malignant brain tumors as well as 297 patients withsubarachnoid hemorrhage (SAH) were treated in the Department of Neurosurgery, University HospitalLeipzig, receiving prophylactic anticoagulation within 48 h. In 2015, prophylactic anticoagulationwas switched from nadroparin to tinzaparin throughout the university hospital. In a retrospectivemanner, the frequency and occurrence of adverse events (rebleeding and thromboembolic events) inconnection with the substance used were analyzed. Statistical analysis was performed using Fisher’sexact test and the chi-squared test. Results: Rebleeding rates were similar in both nadroparin andtinzaparin cohorts in patients being treated for meningioma, glioma, and SAH combined (8.8% vs.10.3%). Accordingly, the rates of overall thromboembolic events were not significantly different (5.5%vs. 4.3%). The severity of rebleeding did not vary. There was no significant difference among subgroupswhen compared for deep vein thrombosis (DVT) or pulmonary embolism (PE). Conclusion:In this retrospective study, tinzaparin seems to be a safe alternative to nadroparin for AC in patientsundergoing brain tumor surgery or suffering from SAH.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)